Acquisition impact The company has recently expanded through the acquisition of Nova Biomedical by Advanced Instruments, creating a larger global life science tools business with integrated capabilities in bioprocessing and clinical diagnostics, signaling cross-sell opportunities across both established and new customer bases.

IVD leadership As a leading privately held IVD company with a broad blood gas, critical care, and glucose analyzer portfolio serving 100+ countries, there are significant opportunities to upsell enhanced analytical instruments, service contracts, and consumables to existing clinical diagnostics customers.

Bioprocessing demand Strength in bioprocessing solutions such as cell line development and real-time culture monitoring indicates potential for selling process optimization tools, real-time analytics, and scalable automation to biopharma and contract development/manufacturing organizations.

Security and reliability Past cybersecurity incident highlights the importance of robust security software, data integrity, and disaster recovery offerings; there is potential to monetize enhanced cybersecurity, data management, and compliant cloud-based services for enterprise customers.

Expansion through partnerships Strategic collaborations like Terumo BCT integration and recent asset acquisitions suggest a sales path focused on bundled solutions, cross-brand deployments, and expansion into new regions and customer segments through joint marketing and integrated product packages.